![](https://endpts.com/wp-content/uploads/2018/01/Roger-Perlmutter-Merck-tile-social.jpg)
Roger Perlmutter, Merck
Catching up with Roche, Merck racks up positive data in frontline triple negative breast cancer
Merck’s Keytruda may not have qualified as a second- or third-line treatment of triple negative breast cancer, but the PD-1 inhibitor is showing promise for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.